Skip to content
View in the app

A better way to browse. Learn more.

Thailand News and Discussion Forum | ASEANNOW

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Libido Drug OK’d for Postmenopause

Featured Replies

IMG_20251216_051807.jpg

 

 

U.S. regulators have expanded approval of the libido-boosting pill Addyi to include women up to age 65 who have gone through menopause, broadening its use beyond premenopausal patients who experience emotional distress from low sexual desire. The change could give more older women a medical option for hypoactive sexual desire disorder (HSDD), though the drug’s impact on overall use and sales remains to be seen. 

 

Addyi, developed by Sprout Pharmaceuticals and first approved by the Food and Drug Administration (FDA) in 2015 for premenopausal women, acts on brain chemicals tied to mood and appetite to modestly boost libido. It had faced criticism over limited effectiveness and notable side effects, such as dizziness and nausea, and carries a boxed warning against using alcohol with the drug because of dangerous drops in blood pressure and risks of fainting. 

 

The drug was initially anticipated to fill a major gap in women’s sexual health but struggled with slow adoption and limited sales since its launch. Experts note diagnosing HSDD is complex, requiring doctors to rule out relationship issues, medical conditions, depression and other factors before prescribing medication, and some psychologists question whether low libido should be defined as a medical disorder. 

 

Sprout welcomed the approval update as a sign of progress in treating women’s sexual health needs, citing persistent work with the FDA to expand access. Critics and clinicians continue to weigh the drug’s benefits against its side effect profile and modest effectiveness, and it remains to be seen how many postmenopausal women will choose this treatment option. 

 

Key Takeaways

 

The FDA has expanded Addyi’s approval to include postmenopausal women up to age 65, increasing its potential patient base. 

 

Addyi’s modest effectiveness and serious side effects, especially when combined with alcohol, continue to influence its use and reception. 

 

Medical debate persists over how to diagnose and treat hypoactive sexual desire disorder in women. 

 

Adapted From 

 

https://apnews.com/article/women-libido-addyi-pill-fda-sexual-health-a6b34c5c94cb31f5908b200097f983da

 

Links

 

https://www.urologytimes.com/view/fda-approves-flibanserin-for-hypoactive-sexual-desire-disorder-in-postmenopausal-women

 

Link Side Effects 

 

https://www.drugs.com/sfx/addyi-side-effects.html

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.